Earnest Partners LLC Raises Holdings in Charles River Laboratories International, Inc. $CRL

Earnest Partners LLC boosted its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 0.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,006,724 shares of the medical research company’s stock after purchasing an additional 8,467 shares during the quarter. Earnest Partners LLC owned about 2.05% of Charles River Laboratories International worth $157,512,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of Charles River Laboratories International by 0.5% during the third quarter. Vanguard Group Inc. now owns 5,839,743 shares of the medical research company’s stock worth $913,686,000 after buying an additional 27,989 shares in the last quarter. Ariel Investments LLC lifted its stake in shares of Charles River Laboratories International by 28.6% in the second quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company’s stock worth $214,751,000 after buying an additional 314,572 shares in the last quarter. Invesco Ltd. boosted its position in Charles River Laboratories International by 1.0% during the third quarter. Invesco Ltd. now owns 1,249,178 shares of the medical research company’s stock worth $195,446,000 after acquiring an additional 12,035 shares during the last quarter. Bank of America Corp DE boosted its position in Charles River Laboratories International by 13.4% during the third quarter. Bank of America Corp DE now owns 1,163,348 shares of the medical research company’s stock worth $182,017,000 after acquiring an additional 137,335 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Charles River Laboratories International by 11.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,130,905 shares of the medical research company’s stock valued at $176,909,000 after acquiring an additional 120,207 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Bank of America raised shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price objective for the company in a research note on Monday, December 15th. Morgan Stanley set a $185.00 target price on Charles River Laboratories International in a report on Monday, December 1st. Barclays dropped their price target on Charles River Laboratories International from $215.00 to $200.00 and set an “overweight” rating for the company in a research report on Thursday, February 19th. Wall Street Zen cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Finally, Mizuho lowered their price objective on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating on the stock in a research note on Friday, February 20th. Ten analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Moderate Buy” and an average price target of $203.57.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $155.61 on Friday. The firm has a 50 day simple moving average of $191.59 and a 200-day simple moving average of $181.00. The stock has a market cap of $7.66 billion, a price-to-earnings ratio of -52.57, a price-to-earnings-growth ratio of 2.66 and a beta of 1.64. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.29 and a quick ratio of 1.02. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $228.88.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, beating the consensus estimate of $2.33 by $0.06. The firm had revenue of $994.23 million for the quarter, compared to analyst estimates of $986.98 million. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The business’s revenue for the quarter was down .8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.66 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Key Charles River Laboratories International News

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Zacks raised its FY2027 EPS view to $11.62 (from $11.30), signaling stronger full‑year outlook and supporting a higher valuation multiple. Zacks FY2027 boost
• Positive Sentiment: Zacks lifted FY2026 EPS to $10.78 (from $10.68), implying near‑term margin or revenue improvement versus prior assumptions. Zacks FY2026 boost
• Positive Sentiment: Zacks published FY2028 EPS of $12.12, reflecting continued expected earnings growth beyond FY2027. Long‑term upgrades can lift investor sentiment. Zacks FY2028 outlook
• Positive Sentiment: Multiple quarterly raises: Q3 2026 to $2.86, Q3 2027 to $3.02, Q4 2026 to $3.02, and Q4 2027 to $3.32 — these sequential upgrades point to improving quarterly momentum. Zacks quarterly upgrades
• Positive Sentiment: Zacks raised mid‑2026 quarterly views (Q2 2026 to $2.85 and Q2/Q3 2026 lifts), indicating expectations for recovery or stronger demand in the upcoming fiscal periods. Zacks mid‑2026 raises
• Neutral Sentiment: Zacks’ estimates differ from the consensus full‑year figure repeatedly cited ($9.36), meaning analyst views remain divergent; the Zacks upgrades imply upside versus consensus but do not change consensus itself. Consensus vs Zacks
• Negative Sentiment: Zacks lowered Q1 2026 EPS from $2.39 to $2.05, a material near‑term cut that could pressure the next quarter’s reported results and short‑term sentiment. Zacks Q1 2026 cut
• Negative Sentiment: Zacks slightly trimmed Q2 2027 to $2.65 (from $2.67), a minor downgrade but another signal of some variability in near‑term cadence. Zacks Q2 2027 trim

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.